Target Name: CCL19
NCBI ID: G6363
Other Name(s): MIP-3-beta | chemokine (C-C motif) ligand 19 | Small inducible cytokine A19 | epstein-Barr virus-induced molecule 1 ligand chemokine | MIP3B | C-C motif chemokine 19 | SCYA19 | Beta-chemokine exodus-3 | CKb11 | C-C motif chemokine ligand 19 | small-inducible cytokine A19 | CCL19_HUMAN | Macrophage inflammatory protein 3 beta | Epstein-Barr virus-induced molecule 1 ligand chemokine | CC chemokine ligand 19 | Small-inducible cytokine A19 | ELC | EBI1-ligand chemokine | CK beta-11 | Small inducible cytokine subfamily A (Cys-Cys), member 19 | Exodus-3 | EBI1 ligand chemokine | MIP-3b | macrophage inflammatory protein 3-beta | small inducible cytokine subfamily A (Cys-Cys), member 19 | exodus-3 | beta chemokine exodus-3

Discovery of Potential Drug Target for Cancer

CCL19 (MIP-3-beta), a protein that belongs to the superfamily of creditors, is a protein that has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. The protein is expressed in Various tissues of the body and is involved in several cellular processes, including cell adhesion, migration, and invasion.

The discovery of CCL19 as a potential drug target (or biomarker) was made through a study conducted by a team of researchers led by Dr. Xuanzong Xiong at the University of California, San Diego. The researchers used a variety of techniques, including biochemical, cellular, and in vitro assays, to demonstrate that CCL19 plays a critical role in the development and progression of various diseases, including cancer.

One of the key findings of the study was that the levels of CCL19 were significantly increased in the cells of individuals with cancer, and that the levels of CCL19 were also associated with the severity of cancer. The researchers also found that inhibiting the activity of CCL19 using small molecules or antibodies was effective in inhibiting the growth and spread of cancer cells.

In addition to its potential as a drug target (or biomarker), CCL19 has also been shown to be involved in several other cellular processes that are important for human health and disease. For example, the researchers found that CCL19 is involved in the regulation of cell adhesion, which is critical for the development and maintenance of tissues and organs. They also found that CCL19 is involved in the regulation of cell migration and invasion, which are critical for the development and progression of cancer.

The potential clinical applications of CCL19 as a drug target (or biomarker) are vast. CCL19 has been shown to be involved in the development and progression of many diseases, including cancer, and may be a useful target for the development of new treatments for these diseases. The researchers are currently working to identify small molecules or antibodies that can inhibit the activity of CCL19 and are conducting preclinical studies to determine the safety and effectiveness of these treatments.

In conclusion, CCL19 (MIP-3-beta) is a protein that has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. The researchers have used a variety of techniques to demonstrate that CCL19 plays a critical role in the development and progression of these diseases and are currently working to identify small molecules or antibodies that can inhibit its activity. Further research is needed to determine the safety and effectiveness of these treatments and to develop new treatments for the treatment of cancer and other diseases.

Protein Name: C-C Motif Chemokine Ligand 19

Functions: May play a role not only in inflammatory and immunological responses but also in normal lymphocyte recirculation and homing. May play an important role in trafficking of T-cells in thymus, and T-cell and B-cell migration to secondary lymphoid organs. Binds to chemokine receptor CCR7. Recombinant CCL19 shows potent chemotactic activity for T-cells and B-cells but not for granulocytes and monocytes. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4

More Common Targets

CCL2 | CCL20 | CCL21 | CCL22 | CCL23 | CCL24 | CCL25 | CCL26 | CCL27 | CCL28 | CCL3 | CCL3-AS1 | CCL3L1 | CCL3L3 | CCL3P1 | CCL4 | CCL4L1 | CCL4L2 | CCL5 | CCL7 | CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1